Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA)

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA)

Abstract only LBA4512 Background: Radium-223 chloride (Ra-223), a targeted alpha-emitter, targets bone metastases (mets) with high-energy alpha-particles of short range (

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical oncology 2012-06, Vol.30 (18_suppl), p.LBA4512-LBA4512
Hauptverfasser: Parker, Chris, Nilsson, Sten, Heinrich, Daniel, O'Sullivan, Joe M., Fossa, Sophie D., Chodacki, Ales, Wiechno, Pawel J., Logue, John P., Seke, Mihalj, Widmark, Anders, Johannessen, Dag Clement, Hoskin, Peter, Bottomley, David, Coleman, Robert Edward, Vogelzang, Nicholas J., O'Bryan-Tear, C. Gillies, Garcia-Vargas, Jose E., Shan, Minghua, Sartor, A. Oliver
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract only LBA4512 Background: Radium-223 chloride (Ra-223), a targeted alpha-emitter, targets bone metastases (mets) with high-energy alpha-particles of short range (
ISSN:0732-183X
1527-7755
1527-7755
DOI:10.1200/jco.2012.30.18_suppl.lba4512